Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.

No definition available.

Name:	abbv_LossContingencyIndividualPlaintiffLawsuitsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of purported class actions filed, pertaining to a loss contingency during the period.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyPurportedClassActionsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248

+ Details

Name:	us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_LitigationCaseAxis=abbv_NiaspanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Legal Proceedings and Contingencies (Details) $ in Billions	1 Months Ended		12 Months Ended
Legal Proceedings and Contingencies (Details) $ in Billions	Aug. 31, 2019 company	Jun. 30, 2016 investment_fund	Dec. 31, 2022 claim lawsuit	Dec. 31, 2022 class_action claim	Dec. 31, 2022 direct_purchaser claim	Dec. 31, 2022 claim end_payor_purchaser	Dec. 31, 2022 company claim	Jun. 30, 2022 USD ($)
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit			4
Number of purported class actions \| class_action				2
Number of healthcare benefit providers acting as plaintiff in lawsuit					1	1
AndroGel antitrust litigation, King Drug Co. of Florence, Inc. v. AbbVie Inc.
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company	3
Bystolic antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company							6
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending \| claim			3,000	3,000	3,000	3,000	3,000
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending \| claim			270	270	270	270	270
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) \| investment_fund		5
Selling, general and administrative \| Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Loss Contingency, Estimate of Possible Loss \| $								$ 2.1